Literature DB >> 24835401

Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1.

Dorothée Duluc1, HyeMee Joo1, Ling Ni1, Wenjie Yin2, Katherine Upchurch2, Dapeng Li1, Yaming Xue1, Peter Klucar1, Sandra Zurawski1, Gerard Zurawski2, SangKon Oh3.   

Abstract

Recent compelling evidence indicates that Th17 confer host immunity against a variety of microbes, including extracellular and intracellular pathogens. Therefore, understanding mechanisms for the induction and activation of Ag-specific Th17 is important for the rational design of vaccines against pathogens. To study this, we employed an in vitro system in which influenza hemagglutinin (HA) 1 was delivered to dendritic cells (DCs) via Dectin-1 using anti-human Dectin-1 (hDectin-1)-HA1 recombinant fusion proteins. We found that healthy individuals maintained broad ranges of HA1-specific memory Th17 that were efficiently activated by DCs targeted with anti-hDectin-1-HA1. Nonetheless, these DCs were not able to induce a significant level of HA1-specific Th17 responses even in the presence of the Th17-promoting cytokines IL-1β and IL-6. We further found that the induction of surface IL-1R1 expression by signals via TCRs and common γ-chain receptors was essential for naive CD4(+) T cell differentiation into HA1-specific Th17. This process was dependent on MyD88, but not IL-1R-associated kinase 1/4. Thus, interruptions in STAT3 or MyD88 signaling led to substantially diminished HA1-specific Th17 induction. Taken together, the de novo generation of pathogen-specific human Th17 requires complex, but complementary, actions of multiple signals. Data from this study will help us design a new and effective vaccine strategy that can promote Th17-mediated immunity against microbial pathogens.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24835401      PMCID: PMC4048825          DOI: 10.4049/jimmunol.1301661

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Authors:  M P Reddy; C A Kinney; M A Chaikin; A Payne; J Fishman-Lobell; P Tsui; P R Dal Monte; M L Doyle; M R Brigham-Burke; D Anderson; M Reff; R Newman; N Hanna; R W Sweet; A Truneh
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

2.  Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection.

Authors:  Michelle N Kelly; Jay K Kolls; Kyle Happel; Joseph D Schwartzman; Paul Schwarzenberger; Crescent Combe; Magali Moretto; Imtiaz A Khan
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  Transforming growth factor-beta induces development of the T(H)17 lineage.

Authors:  Paul R Mangan; Laurie E Harrington; Darrell B O'Quinn; Whitney S Helms; Daniel C Bullard; Charles O Elson; Robin D Hatton; Sharon M Wahl; Trenton R Schoeb; Casey T Weaver
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

5.  Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1.

Authors:  Robert W Carter; Clare Thompson; Delyth M Reid; Simon Y C Wong; David F Tough
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

6.  Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells.

Authors:  Dominik Schenten; Simone A Nish; Shuang Yu; Xiting Yan; Heung Kyu Lee; Igor Brodsky; Lesley Pasman; Brian Yordy; F Thomas Wunderlich; Jens C Brüning; Hongyu Zhao; Ruslan Medzhitov
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

7.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

8.  Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17.

Authors:  Salomé LeibundGut-Landmann; Olaf Gross; Matthew J Robinson; Fabiola Osorio; Emma C Slack; S Vicky Tsoni; Edina Schweighoffer; Victor Tybulewicz; Gordon D Brown; Jürgen Ruland; Caetano Reis e Sousa
Journal:  Nat Immunol       Date:  2007-04-22       Impact factor: 25.606

9.  A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.

Authors:  Caroline Sutton; Corinna Brereton; Brian Keogh; Kingston H G Mills; Ed C Lavelle
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

10.  TLR2 is expressed on activated T cells as a costimulatory receptor.

Authors:  Mousa Komai-Koma; Louise Jones; Graham S Ogg; Damo Xu; Foo Y Liew
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

View more
  18 in total

1.  Dysbiosis of gut microbiota induced the disorder of helper T cells in influenza virus-infected mice.

Authors:  Bin Yu; Cong-qi Dai; Jia Chen; Li Deng; Xian-lin Wu; Sha Wu; Chang-lin Zhao; Zhen-you Jiang; Xiao-yin Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease.

Authors:  Clare E Bryant; Selinda Orr; Brian Ferguson; Martyn F Symmons; Joseph P Boyle; Tom P Monie
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 3.  Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.

Authors:  Andrea J Sant; Katherine A Richards; Jennifer Nayak
Journal:  Curr Opin Immunol       Date:  2018-04-02       Impact factor: 7.486

Review 4.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 5.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

6.  Opposing Roles of Dectin-1 Expressed on Human Plasmacytoid Dendritic Cells and Myeloid Dendritic Cells in Th2 Polarization.

Authors:  HyeMee Joo; Katherine Upchurch; Wei Zhang; Ling Ni; Dapeng Li; Yaming Xue; Xiao-Hua Li; Toshiyuki Hori; Sandra Zurawski; Yong-Jun Liu; Gerard Zurawski; SangKon Oh
Journal:  J Immunol       Date:  2015-06-29       Impact factor: 5.422

7.  C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses.

Authors:  HyeMee Joo; Dapeng Li; Melissa Dullaers; Tae-Whan Kim; Dorothee Duluc; Katherine Upchurch; Yaming Xue; Sandy Zurawski; Roger Le Grand; Yong-Jun Liu; Marcelo Kuroda; Gerard Zurawski; SangKon Oh
Journal:  Immunity       Date:  2014-10-09       Impact factor: 31.745

8.  LOX-1 boosts immunity.

Authors:  SangKon Oh; HyeMee Joo
Journal:  Oncotarget       Date:  2015-09-08

9.  The Adjuvants Polyphosphazene (PCEP) and a Combination of Curdlan Plus Leptin Promote a Th17-Type Immune Response to an Intramuscular Vaccine in Mice.

Authors:  Alyssa Chaffey; Glenn Hamonic; Dylan Chand; George K Mutwiri; Heather L Wilson
Journal:  Vaccines (Basel)       Date:  2021-05-14

10.  Dectin-1 Controls TSLP-Induced Th2 Response by Regulating STAT3, STAT6, and p50-RelB Activities in Dendritic Cells.

Authors:  Chao Gu; Katherine Upchurch; Joshua Horton; Mathew Wiest; Sandra Zurawski; Mark Millard; Robert R Kane; HyeMee Joo; Lisa A Miller; SangKon Oh
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.